Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...
verywellhealth5d
A Guide to Multiple Sclerosis Medications
The medication is administered through an IV infusion once every three months by a healthcare ... 6612.2018132 Multiple Sclerosis Trust. Ocrevus (ocrelizumab). National Multiple Sclerosis Foundation.
pharmaphorum5d
Roche's MS drug Ocrevus priced in line with Novartis rival in UK
Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...